ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Prognostic impact of micrometastases and nodal status in early and advanced oral squamous cell carcinoma.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSentinel lymph node biopsy (SLNB) enhances staging and treatment of oral squamous cell carcinoma (OSCC) by enabling detection of micrometastases (Mi) and isolated tumour cells (ITCs). However, the prognostic significance of these microscopic tumour deposits remains unclear. This study aims to evaluate the impact of Mi, ITCs, and other nodal characteristics on survival and recurrence across all stages of OSCC.
methodsThis retrospective cohort study included all patients with primary OSCC who underwent SLNB at Karolinska University Hospital between March 2019 and October 2024. Clinical and pathological TNM stages were recorded, including the presence of Mi, ITCs, and extranodal extension (ENE). Disease-free survival (DFS) and disease-specific survival (DSS) were analysed using Kaplan–Meier estimates and Cox proportional hazards models.
resultsA total of 259 patients were included. 66.4% presented with early-stage disease (cT1-T2N0). Recurrence occurred in 15.8% of cases. Increasing tumour stage and nodal burden were associated with poorer DFS and DSS (p < 0.0001). Mi was identified in 11.0% of patients with early-stage OSCC and in 3.4% of cases with advanced disease. Three-year DFS was 88.0% in pN0 disease, 100% for pN0itc, 73.2% for pNmi, and 57.9% in patients with macrometastasis (pN +).
conclusionsTumour stage, nodal burden and ENE are strong predictors of DFS and DSS in OSCC. Patients with Mi had outcomes comparable to those with pN1 disease, whereas ITCs did not negatively affect prognosis. These findings support classifying Mi as metastatic disease, and underscore the value of SLNB in management across all stages of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.